Supriya Lifescience IPO

Supriya Lifescience Ltd.

₹14,310 /54 sharesMinimum Investment

Supriya Lifescience IPO Details

Bidding DatesMin. InvestmentLot SizePrice Range
16 Dec ‘21 - 20 Dec ‘21₹14,31054₹265 - ₹274
Issue SizeIPO Doc
700.00Cr
RHP PDF

Subscription Status As on 20 Dec '21, 8:00 PM

  • Retail Individual Investor
    56.01x
  • Non-Institutional Investor
    161.22x
  • Qualified Institutional Buyers
    31.83x

About Supriya Lifescience

Supriya Lifescience supplies active pharmaceuticals ingredients (APIs), with a focus on research and development. It has 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anesthetic, vitamin, anti-asthmatic, and antiallergic. Its products are registered with various international regulatory authorities such as USFDA, EDQM, NMPA (previously known as SFDA), KFDA, PMDA, TGA, and Taiwan FDA.;
Parent Organisation
Supriya Lifescience Ltd.
Founded
2008
Managing Director
Satish Waman Wagh
Supriya Lifescience IPO Review, Date,Price,Details | Aleena Rais | Latest IPO news | Upcoming IPO

Strengths & Risks

  • Significant scale with a leadership position across key & niche products.
  • A backward integrated business model that ensures a steady supply of intermediaries.
  • Geographically diversified revenues with a global presence across 86 countries.
  • Advanced manufacturing and research and development capabilities.
  • Consistent strong financial performance due to a de-risked business model.
  • Any reduction in demand for a set of products that the company relies on for a significant portion of its revenue.
  • Dependence on a few customers for a significant portion of revenue.
  • Its international operations expose it to complex management, legal, tax, and economic risks.
  • Failure to successfully develop or commercialise new products in a timely manner.
  • Any failure to comply with regulations prescribed by governments and regulatory agencies or obtain, maintain, or renew its statutory and regulatory licenses, permits, and approvals required to operate its business.
  • Any manufacturing or quality control problems.
  • Non-compliance with and changes in, safety, health, environmental, and labor laws and other applicable regulations.
  • Any delay in production at, disruption or shutdown of its manufacturing facility, or failure to achieve optimal capacity utilisation.
  • Changes in technology may render its current technologies obsolete or require it to make substantial capital investments..
  • Inability to accurately forecast demand for its products and manage its inventory.
  • Inability to patent new processes and protect its proprietary information or other intellectual property.

Financials

*All values are in Rs. Cr
No Graph Data To Display

Application details

Apply asPrice bandApply upto
For Supriya Lifescience IPO, eligible investors can apply as
ⓒ 2016-2024 Groww. All rights reserved, Built with in India
MOST POPULAR ON GROWWVERSION - 4.7.4
STOCK MARKET INDICES:  S&P BSE SENSEX |  S&P BSE 100 |  NIFTY 100 |  NIFTY 50 |  NIFTY MIDCAP 100 |  NIFTY BANK |  NIFTY NEXT 50
MUTUAL FUNDS COMPANIES:  GROWWMF |  SBI |  AXIS |  HDFC |  UTI |  NIPPON INDIA |  ICICI PRUDENTIAL |  TATA |  KOTAK MAHINDRA |  DSP |  CANARA ROBECO |  SUNDARAM |  MIRAE ASSET |  BANDHAN |  FRANKLIN TEMPLETON |  PPFAS |  MOTILAL OSWAL |  INVESCO |  EDELWEISS |  ADITYA BIRLA SUN LIFE |  LIC |  HSBC |  NAVI |  QUANTUM |  UNION |  IDBI |  ITI |  MAHINDRA MANULIFE |  360 ONE |  BOI |  TAURUS |  JM FINANCIAL |  PGIM |  SHRIRAM |  BARODA BNP PARIBAS |  QUANT |  WHITEOAK CAPITAL |  TRUST |  SAMCO |  NJ |  BAJAJ

ABOUT GROWW